Literature DB >> 18684871

Further progress in CLL therapy.

Emili Montserrat1.   

Abstract

Year:  2008        PMID： 18684871     DOI： 10.1182/blood-2008-05-155721

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.

Authors:  Spyridon Arampatzis; Nikolaos Giannakoulas; Vassilios Liakopoulos; Theodoros Eleftheriadis; Panagiota Kourti; Foteini Karasavvidou; Panagiota Matsouka; Ioannis Stefanidis
Journal:  BMC Nephrol       Date:  2011-07-05       Impact factor: 2.388

2.  Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.

Authors:  S Kasar; C Underbayev; Y Yuan; M Hanlon; S Aly; H Khan; V Chang; M Batish; T Gavrilova; F Badiane; H Degheidy; G Marti; E Raveche
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.